Skip to content
drillr.ai
Sign up

IDXX

IDEXX LABORATORIES INC /DE

NASDAQ · Healthcare · Medical - Diagnostics & Research · US

$692.68
+3.07%
Ask drillr

  • Nov 3, 2026, 15:31 UTC

    IDEXX LABORATORIES INC /DE (IDXX) crossed above its 200-day moving average.

    Source:

  • Nov 2, 2026, 14:49 UTC

    IDEXX LABORATORIES INC /DE shares rose 19.4%.

    Source:

  • Nov 2, 2026, 13:46 UTC

    IDEXX LABORATORIES INC /DE reported quarterly earnings of $3.98 per share, compared with $3.40 per share a year earlier.

    Source:

  • Nov 2, 2026, 11:36 UTC

    IDEXX Laboratories reported Q3 2026 revenue of $1.214 billion, net income of $317.145 million and diluted EPS of $4.01, and provided FY2026 revenue guidance of $4.741 billion to $4.767 billion and diluted EPS guidance of $14.96 to $15.16.

    Source:

  • Oct 1, 2026, 15:30 UTC

    IDEXX Laboratories scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before market open, with an analyst conference call at 8:30 a.m. ET that day.

    Source:

  • Sep 30, 2026, 13:00 UTC

    IDEXX Laboratories acquired CoVetAI Inc., prompting Chicago Pacific Founders to exit its investment in the company.

    Source:

  • Sep 17, 2026, 07:00 UTC

    IDEXX Laboratories expanded its Faecal Dx antigen testing platform in the United Kingdom with taeniid tapeworm detection for broader intestinal parasite screening.

    Source:

  • Sep 16, 2026, 11:00 UTC

    IDEXX Laboratories acquired CoVetAI to advance veterinary workflow intelligence.

    Source:

  • Aug 14, 2026, 18:03 UTC

    IDEXX Laboratories outlined at its 2026 Investor Day a pipeline of diagnostic, software, and AI offerings, including cancer tests, targeting a $45 billion global companion-animal testing opportunity.

    Source:

  • Aug 11, 2026, 11:00 UTC

    IDEXX launched the Catalyst proBNP Test, the first and only dual-species point-of-care NT-proBNP assay for cardiac assessment in dogs and cats, at its Westbrook, Maine facility.

    Source:

  • Aug 4, 2026, 10:30 UTC

    IDEXX Laboratories reported second quarter 2026 revenues of $1,217 million, up 10% as reported and 9% organic, with growth across its business segments.

    Source:

  • Jun 25, 2026, 00:00 UTC

    Jonathan J. Mazelsky was appointed as a Class II director of Insulet Corp, effective July 1, 2026.